We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Right prescription

15 November 2017 By Christopher Beddor

Shanghai Pharmaceuticals agreed to buy the China drugs-distribution business of Cardinal Health for $557 million. It looks like a reasonable deal for both sides. It also highlights how even well-meaning medical reforms could prompt some foreign firms to look for the exits.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)